Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependencea
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The potential for deriving new psychotherapeutic medications from natural sources has led to renewed interest in rain forest plants as a source of lead compounds for the development of antiaddiction medications. Ibogaine is an indole alkaloid found in the roots of Tabernanthe iboga (Apocynaceae family), a rain forest shrub that is native to equatorial Africa. Ibogaine is used by indigenous peoples in low doses to combat fatigue, hunger and in higher doses as a sacrament in religious rituals. Members of American and European addict self‐help groups have claimed that ibogaine promotes long‐term drug abstinence from addictive substances, including psychostimulants and cocaine. Anecdotal reports attest that a single dose of ibogaine eliminates withdrawal symptoms and reduces drug cravings for extended periods of time. The purported antiaddictive properties of ibogaine require rigorous validation in humans. We have initiated a rising tolerance study using single administration to assess the safety of ibogaine for the treatment of cocaine dependency. The primary objectives of the study are to determine safety, pharmacokinetics and dose effects, and to identify relevant parameters of efficacy in cocaine‐dependent patients. Pharmacokinetic and pharmacodynamic characteristics of ibogaine in humans are assessed by analyzing the concentration‐time data of ibogaine and its desmethyl metabolite (noribogaine) from the Phase I trial, and by conducting in vitro experiments to elucidate the specific disposition processes involved in the metabolism of both parent drug and metabolite. The development of clinical safety studies of ibogaine in humans will help to determine whether there is a rationale for conducting efficacy trials in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gawin, F. H., & Ellinwood, E. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805053181806 · Cited by 965
Mash, D. C., Staley, J. K., Pablo, J. P., Holohean, A. M., Hackman, J. C., & Davidoff, R. A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11608-y · Cited by 80
Self-citation
Cited by
Neurobiologic processes in drug reward and addiction
Adinoff, B. (2004) · Harvard Review of Psychiatry · doi:10.1080/10673220490910844 · Cited by 546
Majić, T., Schmidt, T. T., & Gallinat, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568040 · Cited by 261
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246
“Also, because of its influence on the NMDA receptor, it is similar to other NMDA receptor ligands such as acomprosate and ibogaine (Mash et al., 1998; Sass, Soyka, Mann, & Zieglgansberger, 1996), and may possess similar anti-craving properties.”
BackgroundInfluentialClinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
“The neuropharmacology of ibogaine is complex and remains incompletely understood (Koenig & Hilber, 2015; Mash et al., 1998, 2001).”
Background(2001) · The Alkaloids: Chemistry and Biology · doi:10.1016/s0099-9598(01)56006-x · Cited by 64
Metadata
- Authors
- MASH, D. C., KOVERA, C. A., BUCK, B. E., NORENBERG, M. D., SHAPSHAK, P., HEARN, W. L., & SANCHEZ‐RAMOS, J.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 1998-05
- Volume
- 844
- Issue
- 1
- Pages
- 274-292
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W4320800338
- Cited by
- 112
- References
- 2
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependencea. https://app.cochat.ai/papers/10.1111/j.1749-6632.1998.tb08242.x
- The paper
- MASH, D. C., KOVERA, C. A., BUCK, B. E., NORENBERG, M. D., SHAPSHAK, P., HEARN, W. L., & SANCHEZ‐RAMOS, J. (1998). Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependencea. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1998.tb08242.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.